The global glioblastoma multiforme treatment drugs market is anticipated to grow at a significant CAGR during the forecast period (2024-2031). The major factors that are fuelling the market growth include the growing prevalence of glioblastoma multiforme, increasing R&D, and favorable regulatory scenarios, which are anticipated to boost the market growth. The presence of a strong pipeline is expected to act as a major driver for the glioblastoma multiforme (GBM) treatment market during the forecast period. The increasing incidence of brain tumors is expected to drive the growth of the global glioblastoma multiforme treatment market over the forecast period.
Get Free Sample link @ https://www.omrglobal.com/request-sample/glioblastoma-multiforme-treatment-drugs-market
The increasing approval for novel therapy and combination therapy is expected to drive the market in the coming years. For instance, in June 2019, the U.S. FDA approved Pfizer’s Zirabev, a biosimilar for Avastin, for the treatment of recurrent glioblastoma, NSCLC, and colorectal cancer, among others. In January 2020, the company launched its product in the U.S.
The global glioblastoma multiforme treatment drugs market analysis includes some of the key market players such as Sanofi S.A., Eli Lilly and Company, AstraZeneca plc., Astellas Pharma Inc., and Johnson & Johnson (Janss en Pharmaceuticals), among others. To maintain a strong position in the market, these market players are adopting various strategic moves, such as product launches, partnerships, collaborations, and mergers and acquisitions. For instance, in November 2019, the U.S. FDA accepted Samsung’s BLA application for its SB8 bevacizumab biosimilar candidate, which will increase the potential to launch products in the coming years.
Full report of Glioblastoma Multiforme Treatment Drugs Market available @ https://www.omrglobal.com/industry-reports/glioblastoma-multiforme-treatment-drugs-market
Market Coverage
- Segment Covered
- Regions Covered- Globally
Competitive Landscape: Bausch Health Companies Inc., Nestlé (Galderma), Leo Pharma Inc., Hovione FarmaCiencia SA, and Aclaris Therapeutics, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominates the market in base year?
- Which segment and region will project fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Glioblastoma Multiforme Treatment Drugs Market by Segment
By Treatment
- Surgery
- Chemotherapy
- Radiation Therapy
- Others
By Drug Class
- Temozolomide
- Bevacizumab
- Lomustine
- Others
By End-Use
- Hospitals
- Clinics
- Ambulatory Surgical Centers
Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/glioblastoma-multiforme-treatment-drugs-market
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
